

# Eleftheria Hatzimichael

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4506355/publications.pdf>

Version: 2024-02-01

147  
papers

3,904  
citations

126907

33  
h-index

138484

58  
g-index

149  
all docs

149  
docs citations

149  
times ranked

7398  
citing authors

#	ARTICLE	IF	CITATIONS
1	Leishmaniasis mimicking multiple myeloma. <i>International Journal of Laboratory Hematology</i> , 2022, 44, 44-46.	1.3	2
2	Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma. <i>In Vivo</i> , 2022, 36, 1302-1315.	1.3	2
3	Autophagy and cellular senescence in classical Hodgkin lymphoma. <i>Pathology Research and Practice</i> , 2022, 236, 153964.	2.3	4
4	Microenvironmental Features Driving Immune Evasion in Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Diseases (Basel, Switzerland)</i> , 2022, 10, 33.	2.5	4
5	A Novel $\alpha$ -Thalassemia Deletion Associated with Severe Anemia at Birth and a $\beta$ -Thalassemia Intermedia Phenotype Later in Life in Three Generations of a Greek Family. <i>Hemoglobin</i> , 2021, 45, 351-354.	0.8	3
6	Development of Classic Hodgkin Lymphoma after successful treatment of primary mediastinal large b-cell lymphoma: results from a well-defined database. <i>Leukemia Research</i> , 2021, 100, 106479.	0.8	3
7	The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes. <i>British Journal of Haematology</i> , 2021, 192, 978-987.	2.5	4
8	Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome. <i>Leukemia</i> , 2021, 35, 1745-1750.	7.2	15
9	Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes. <i>Blood Cancer Journal</i> , 2021, 11, 30.	6.2	2
10	Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies. <i>Annals of Hematology</i> , 2021, 100, 2279-2292.	1.8	10
11	Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2021, 39, 336-348.	1.7	25
12	Novel Therapeutic Advances in $\beta$ -Thalassemia. <i>Biology</i> , 2021, 10, 546.	2.8	19
13	Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP. <i>Oncologist</i> , 2021, 26, 597-609.	3.7	15
14	Subdiaphragmatic extranodal localizations at diagnosis of primary mediastinal large B-cell lymphoma: an impressive, rare presentation with no independent effect on prognosis. <i>Leukemia Research</i> , 2021, 107, 106595.	0.8	3
15	CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome. <i>Pathology Research and Practice</i> , 2021, 225, 153567.	2.3	11
16	Paraneoplastic Intrahepatic Cholestasis in Supradiaphragmatic Classical Hodgkin Lymphoma Successfully Treated With Brentuximab Vedotin: A Case Report and Review of the Literature. <i>In Vivo</i> , 2021, 35, 1951-1957.	1.3	2
17	Myelodysplastic Syndromes (MDS) Presenting with Isolated Thrombocytopenia: Characteristics, Outcomes, and Clinical Presentation Differences from Immune Thrombocytopenic Purpura (ITP). <i>Blood</i> , 2021, 138, 1535-1535.	1.4	3
18	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacytidine: Results From the Hellenic 5-Azacytidine Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 114-121.	0.4	5
20	Effectiveness of 5-Azacytidine in older patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 121-124.	1.0	5
21	Hyponatremia in Patients with Hematologic Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 3721.	2.4	10
22	The contribution of metabolic parameters of FDG PET/CT prior and during therapy of adult patients with lymphomas. <i>Annals of Nuclear Medicine</i> , 2020, 34, 707-717.	2.2	9
23	Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096612.	2.5	9
24	Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes. <i>Hematological Oncology</i> , 2020, 38, 541-553.	1.7	3
25	Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study. <i>EJHaem</i> , 2020, 1, 255-261.	1.0	2
26	Cyanosis Due to Methemoglobinemia as the Presenting Sign of Glucose-6-Phosphate Dehydrogenase Deficiency in a Child. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, Publish Ahead of Print, e1140-e1144.	0.6	1
27	The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5-azacytidine: Results from the Hellenic 5-azacytidine registry. <i>Cancer Medicine</i> , 2019, 8, 2056-2063.	2.8	6
28	Chronic myelomonocytic leukemia treated with 5-azacytidine – results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system. <i>Leukemia and Lymphoma</i> , 2019, 60, 1721-1730.	1.3	12
29	The Prognostic Significance of Monocytopenia in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2019, 134, 5427-5427.	1.4	0
30	Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group. <i>Blood</i> , 2019, 134, 5423-5423.	1.4	0
31	Primary Bone Non-Hodgkin's Lymphoma: A Specific Clinical Entity with Aggressive Clinical Course and High Cure Rate - Retrospective Analysis of 102 Patients from Greece. <i>Blood</i> , 2019, 134, 5340-5340.	1.4	1
32	The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacytidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group. <i>American Journal of Hematology</i> , 2018, 93, 895-901.	4.1	10
33	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience. <i>Hematological Oncology</i> , 2018, 36, 174-181.	1.7	15
34	Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. <i>Annals of Hematology</i> , 2018, 97, 1671-1682.	1.8	17
35	Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group. <i>Leukemia Research</i> , 2018, 71, 55-59.	0.8	0
36	The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group. <i>Hematological Oncology</i> , 2018, 36, 693-700.	1.7	14

#	ARTICLE	IF	CITATIONS
37	Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. <i>Hematological Oncology</i> , 2018, 36, 645-650.	1.7	6
38	Characteristics of Long-Term Survival of Patients with MDS Treated with 5-Azacytidine. Results from the Hellenic 5-Azacytidine Registry. <i>Blood</i> , 2018, 132, 3107-3107.	1.4	0
39	Prognostic Significance of Severe Thrombocytopenia in Overall Survival of Patients with Myelodysplastic Syndromes Treated with Azacytidine. a Multicenter Study By the Hellenic MDS Study Group. <i>Blood</i> , 2018, 132, 1822-1822.	1.4	0
40	Sitosterolemia: A multifaceted metabolic disorder with important clinical consequences. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1095-1100.	1.5	23
41	SLCO1B3 screening in colorectal cancer patients using High-Resolution Melting Analysis method and immunohistochemistry. <i>Tumor Biology</i> , 2017, 39, 101042831769117.	1.8	5
42	Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. <i>Cancer Letters</i> , 2017, 400, 243-251.	7.2	26
43	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	2.2	37
44	Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms. <i>Clinical and Experimental Medicine</i> , 2017, 17, 291-304.	3.6	45
45	Prognostic Factors for Immune Thrombocytopenia Outcome in Greek Children: A Retrospective Single-Centered Analysis. <i>Advances in Hematology</i> , 2017, 2017, 1-7.	1.0	9
46	Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review. <i>Case Reports in Hematology</i> , 2017, 2017, 1-5.	0.4	8
47	2017 Clinical trials update in new treatments of $\beta$ -thalassemia. <i>American Journal of Hematology</i> , 2016, 91, 1135-1145.	4.1	52
48	Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment. <i>Molecular and Clinical Oncology</i> , 2016, 5, 23-26.	1.0	4
49	Megaloblastic anemia presenting with skin hyperpigmentation. <i>International Journal of Hematology</i> , 2016, 103, 479-480.	1.6	1
50	Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study. <i>Blood</i> , 2016, 128, 5476-5476.	1.4	0
51	Validation of the Revised International Prognostic Scoring System in 2582 Patients with Myelodysplastic Syndrome: A Multicenter Study By the Hellenic MDS Study Group. <i>Blood</i> , 2016, 128, 2004-2004.	1.4	0
52	Rare variants in the spectrum of human herpesvirus 8/Epstein-Barr virus "copositive lymphoproliferations. <i>Human Pathology</i> , 2015, 46, 1566-1571.	2.0	25
53	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1106-15.	7.1	376
54	Abstract 3997: Expression profiling of a panel of apoptosis-associated microRNAs in acute myeloid leukemia identifies differentially expressed microRNAs that target epigenetic modifiers. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
55	Expression Profiling of a Panel of Apoptosis Related Micrnas in Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 4971-4971.	1.4	2
56	Ruxolitinib Efficacy and Safety in Myelofibrosis: A Multicenter Observational Study. <i>Blood</i> , 2015, 126, 5192-5192.	1.4	0
57	Profile of pacritinib and its potential in the treatment of hematologic disorders. <i>Journal of Blood Medicine</i> , 2014, 5, 143.	1.7	21
58	How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 639-642.	3.1	3
59	Polycomb group proteins and MYC: the cancer connection. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 257-269.	5.4	51
60	Real-world data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. <i>Annals of Hematology</i> , 2014, 93, 129-139.	1.8	38
61	The human platelet: strong transcriptome correlations among individuals associate weakly with the platelet proteome. <i>Biology Direct</i> , 2014, 9, 3.	4.6	77
62	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014, 28, 2075-2079.	7.2	57
63	Direct Binding of Bcl-2 Family Proteins by Quercetin Triggers Its Pro-Apoptotic Activity. <i>ACS Chemical Biology</i> , 2014, 9, 2737-2741.	3.4	57
64	DLK1-DIO3 imprinted cluster in induced pluripotency: landscape in the mist. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 4421-4430.	5.4	28
65	Delta-Like Homologue 1 and Its Role in the Bone Marrow Niche and Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 451-455.	0.4	5
66	A blood test to identify when melanoma metastasizes: a reality for melanoma management?. <i>Melanoma Management</i> , 2014, 1, 11-14.	0.5	0
67	Hypercalcemia Remains an Adverse Prognostic Factor for Newly Diagnosed Patients with Symptomatic Multiple Myeloma in the Era of Novel Anti-Myeloma Therapies, Independently of Age, ISS Stage and Treatment Type: An Analysis of 2129 Patients. <i>Blood</i> , 2014, 124, 2113-2113.	1.4	3
68	Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. <i>EXCLI Journal</i> , 2014, 13, 954-76.	0.7	6
69	Noncoding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome. <i>International Journal of Cancer</i> , 2013, 133, 267-274.	5.1	81
70	Clinical trial design in biosimilar drug development. <i>Investigational New Drugs</i> , 2013, 31, 479-487.	2.6	41
71	The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 795-814.	5.4	246
72	Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1278-1285.	0.7	44

#	ARTICLE	IF	CITATIONS
73	Revisiting bleomycin from pathophysiology to safe clinical use. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 90-100.	4.4	86
74	Adipocytokines are related to haemolytic and inflammatory biomarkers in sickle cell beta thalassaemia. <i>British Journal of Haematology</i> , 2013, 163, 142-144.	2.5	3
75	Cancer Epigenetics: New Therapies and New Challenges. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-9.	2.5	66
76	Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in glioblastoma. <i>Cell Death and Disease</i> , 2013, 4, e458-e458.	6.3	133
77	Metronomic chemotherapy beyond misconceptions. <i>Haematologica</i> , 2013, 98, e145-e145.	3.5	3
78	Estimated Glomerular Filtration Rate Calculated By The CKD-EPI Formula Has Improved Prognostic Ability Over MDRD Formula In Patients With Newly Diagnosed, Symptomatic, Multiple Myeloma: Analysis In 1937 Patients. <i>Blood</i> , 2013, 122, 1867-1867.	1.4	1
79	Towards a Reference Human Platelet Transcriptome: Evaluation Of Inter-Individual Correlations and Its Relationship With a Platelet Proteome. <i>Blood</i> , 2013, 122, 2297-2297.	1.4	0
80	Greek Registry Of Essential Thrombocythemia: Baseline Characteristics and Therapeutic Strategy. <i>Blood</i> , 2013, 122, 4084-4084.	1.4	0
81	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. <i>Blood</i> , 2013, 122, 1866-1866.	1.4	0
82	Decoding The BH3-Mimetic Pro-Apoptotic Activity Of Quercetin In Jurkat Cells. <i>Blood</i> , 2013, 122, 1672-1672.	1.4	0
83	Gene mutations and molecularly targeted therapies in acute myeloid leukemia. <i>American Journal of Blood Research</i> , 2013, 3, 29-51.	0.6	36
84	Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. <i>American Journal of Blood Research</i> , 2013, 3, 181-5.	0.6	1
85	NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. <i>British Journal of Cancer</i> , 2012, 106, 1446-1452.	6.4	76
86	Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis. <i>Cell Death and Disease</i> , 2012, 3, e342-e342.	6.3	107
87	Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. <i>Leukemia and Lymphoma</i> , 2012, 53, 1709-1713.	1.3	13
88	NT5E CpG island methylation is a favourable breast cancer biomarker. <i>British Journal of Cancer</i> , 2012, 107, 75-83.	6.4	36
89	The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. <i>British Journal of Cancer</i> , 2012, 107, 1423-1432.	6.4	17
90	Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients. <i>Supportive Care in Cancer</i> , 2012, 20, 1353-1360.	2.2	21

#	ARTICLE	IF	CITATIONS
91	Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era. <i>European Journal of Haematology</i> , 2012, 89, 10-15.	2.2	28
92	Beyond mRNAs and Mirnas: Unraveling the Full-Spectrum of the Normal Human Platelet Transcriptome Through Next-Generation Sequencing. <i>Blood</i> , 2012, 120, 3298-3298.	1.4	3
93	Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in cancer. <i>Oncotarget</i> , 2012, 3, 78-83.	1.8	30
94	Abstract 4550: NT5E promoter methylation is a favorable breast cancer epigenetic biomarker. , 2012, , .		0
95	Epigenetic inactivation to target the arginine biosynthetic pathway in multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18567-e18567.	1.6	1
96	Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents. <i>Blood</i> , 2012, 120, 948-948.	1.4	0
97	Leptin and Adiponectin Blood Levels in Patients with Steady State Sickle Cell Disease Are Related to Chronic Hemolytic and Inflammatory Biomarkers. <i>Blood</i> , 2012, 120, 1012-1012.	1.4	1
98	Tissue Factor Pathway Inhibitor 2 (TFPI2) Is Commonly Methylated in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4617-4617.	1.4	0
99	1037 POSTER The Prolyl-3-hydroxylases (P3H) and P3H-related Genes CRTAP and SC65 Are Novel Transcriptionally Silenced Genes in Burkitt's Lymphoma. <i>European Journal of Cancer</i> , 2011, 47, S107.	2.8	0
100	Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. <i>Annals of Hematology</i> , 2011, 90, 1037-1045.	1.8	37
101	MEG3 imprinted gene contribution in tumorigenesis. <i>International Journal of Cancer</i> , 2011, 129, 773-779.	5.1	244
102	Targeting Oncogenic Protein-Protein Interactions by Diversity Oriented Synthesis and Combinatorial Chemistry Approaches. <i>Molecules</i> , 2011, 16, 4408-4427.	3.8	20
103	Polo-like Kinase Plk2 Is an Epigenetic Determinant of Chemosensitivity and Clinical Outcomes in Ovarian Cancer. <i>Cancer Research</i> , 2011, 71, 3317-3327.	0.9	56
104	Frequency and Prognostic Significance of Hypercalcemia in Patients with Multiple Myeloma: An Analysis of the Database of the Greek Myeloma Study Group. <i>Blood</i> , 2011, 118, 5083-5083.	1.4	4
105	Clinical Features and Outcome of Newly Diagnosed, Symptomatic Patients with Multiple Myeloma ≥80 Years of Age: An Analysis of the Greek Myeloma Study Group. <i>Blood</i> , 2011, 118, 5084-5084.	1.4	5
106	Methylation Status of the Collagen Prolyl-3 Hydroxylases (C-P3H) and C-P4H Genes in Multiple Myeloma: P3H2 Is Selectively Methylated. <i>Blood</i> , 2011, 118, 4639-4639.	1.4	0
107	Epigenetic Inactivation Targets the Arginine Biosynthetic Pathway At Two Levels in Multiple Myeloma. <i>Blood</i> , 2011, 118, 4640-4640.	1.4	0
108	Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. <i>Haematologica</i> , 2010, 95, 406-414.	3.5	48

#	ARTICLE	IF	CITATIONS
109	The prolyl-4-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia. <i>European Journal of Haematology</i> , 2010, 84, 47-51.	2.2	43
110	CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia Research</i> , 2010, 34, 148-153.	0.8	150
111	DUSP16 is an epigenetically regulated determinant of JNK signalling in Burkitt's lymphoma. <i>British Journal of Cancer</i> , 2010, 103, 265-274.	6.4	25
112	Hematopoietic stem cell transplantation. <i>Stem Cells and Cloning: Advances and Applications</i> , 2010, 3, 105.	2.3	76
113	Serum Adipocytokine and Vascular Inflammation Marker Levels in Beta-Thalassaemia Major Patients. <i>Acta Haematologica</i> , 2010, 124, 191-196.	1.4	18
114	Cytokine and Adhesion Molecule Expression Evolves Between the Neutrophilic and Lymphocytic Phases of Viral Meningitis. <i>Journal of Interferon and Cytokine Research</i> , 2010, 30, 661-665.	1.2	5
115	Study of specific genetic and epigenetic variables in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2270-2274.	1.3	27
116	The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. <i>Annals of Oncology</i> , 2009, 20, 775-779.	1.2	144
117	P027 Prognostic significance of less frequent or rare chromosome abnormalities in Greek patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, S73-S74.	0.8	0
118	P113 Treatment with lenalidomide for patients with myelodysplastic syndromes (MDS): report of the Hellenic experience on 73 patients. A retrospective analysis of the Hellenic MDS Study Group. <i>Leukemia Research</i> , 2009, 33, S125.	0.8	0
119	Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia. <i>Leukemia Research</i> , 2009, 33, 1272-1275.	0.8	12
120	von Hippel-Lindau Methylation Status in Patients with Multiple Myeloma: A Potential Predictive Factor for the Development of Bone Disease. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 239-242.	1.4	32
121	Methylation analysis of the von Hippel-Lindau gene in acute myeloid leukaemia and myelodysplastic syndromes. <i>Leukemia</i> , 2008, 22, 1293-1295.	7.2	8
122	The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms. <i>British Journal of Haematology</i> , 2008, 141, 557-558.	2.5	8
123	Promoter Hypermethylation of the MEG3 (DLK1/MEG3) Imprinted Gene in Multiple Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 171-175.	1.4	88
124	Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. <i>Hematology</i> , 2007, 12, 481-486.	1.5	18
125	Cryptococcus lung infection complicating fludarabine treatment in a chronic lymphocytic leukemia patient. <i>Leukemia Research</i> , 2007, 31, 119-120.	0.8	5
126	Epigenetic Profiling Identifies EGLN3 as a Frequent Target for Transcriptional Silencing in Plasma Cell Neoplasias. <i>Blood</i> , 2007, 110, 2132-2132.	1.4	6



#	ARTICLE	IF	CITATIONS
127	Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support. <i>International Journal of Laboratory Hematology</i> , 2006, 28, 416-418.	0.2	19
128	Host Pharmacogenetics in the Treatment of HIV and Cancer. <i>Current Drug Safety</i> , 2006, 1, 107-116.	0.6	2
129	The genomics of new drugs in sickle cell disease. <i>Pharmacogenomics</i> , 2006, 7, 909-917.	1.3	4
130	The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma. <i>Annals of Oncology</i> , 2006, 17, 503-506.	1.2	16
131	C-Reactive Protein and Vascular Cell Adhesion Molecule-1 as Markers of Severity in Sickle Cell Disease. <i>Archives of Internal Medicine</i> , 2006, 166, 366.	3.8	20
132	Serum levels of soluble interleukin-2 receptor alpha (sIL-2R $\alpha$ ) as a predictor of outcome in brucellosis. <i>Journal of Infection</i> , 2005, 51, 206-210.	3.3	36
133	Serum interleukin (IL-1, IL-2, sIL-2R $\alpha$ , IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. <i>British Journal of Haematology</i> , 2005, 130, 709-715.	2.5	116
134	Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2005, 11, 272-275.	3.0	70
135	The Rationale and Development of New Drugs to Treat HIV Infection. <i>Medicinal Chemistry</i> , 2005, 1, 635-642.	1.5	5
136	Treatment of $\beta^2$ -Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion Molecules. <i>Acta Haematologica</i> , 2004, 111, 189-195.	1.4	22
137	Recombinant human erythropoietin therapy in a transfusion-dependent $\beta^2$ -thalassemia major patient. <i>Annals of Hematology</i> , 2001, 80, 492-495.	1.8	14
138	Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia. <i>European Journal of Haematology</i> , 2001, 66, 1-6.	2.2	40
139	Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2001, 66, 31-36.	2.2	7
140	Treatment of plasma cell leukemia with vincristine, liposomal doxorubicin and dexamethasone. <i>European Journal of Haematology</i> , 2001, 67, 51-53.	2.2	28
141	Prolonged interferon-alpha-2b treatment of hairy cell leukemia patients. <i>European Journal of Haematology</i> , 2000, 64, 350-351.	2.2	3
142	The role of cytokines in sickle cell disease. <i>Annals of Hematology</i> , 2000, 79, 407-413.	1.8	87
143	Alpha-2-Macroglobulin and Interleukin-6 Levels in Steady-State Sickle Cell Disease Patients. <i>Acta Haematologica</i> , 2000, 104, 164-168.	1.4	24
144	A Patient with Multiple Myeloma, Amyloidosis and Light-Chain Deposition Disease in Kidneys with a Long Survival. <i>Acta Haematologica</i> , 1999, 101, 202-205.	1.4	8

#	ARTICLE	IF	CITATIONS
145	Combination therapy with interferon-alpha-2b and hydroxyurea in patients with chronic myelogenous leukemia. European Journal of Internal Medicine, 1999, 10, 27-31.	2.2	1
146	Serum beta $\alpha$ 2 $\alpha$ microglobulin, TNF $\alpha$ and interleukins in myeloproliferative disorders. European Journal of Haematology, 1999, 63, 19-25.	2.2	17
147	Rifampicin-Induced Thrombocytopenia: A Case Report and Short Review of the Literature. European Medical Journal (Chelmsford, England), 0, , .	3.0	0